PF614-102

· Ensysce Biosciences

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PF614-102, covering 2024-09-24 to 2024-09-24. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of Oral PF614 Relative to OxyContin (PF614-102) [Phase 1]